Cycling GLP-1 Therapy Linked to Treatment Resistance and Progressive Fat Gain

A new study in JCI Insight reveals a hidden cost of stop-start GLP-1 receptor agonist (GLP-1 RA) use. In a mouse model, researchers compared continuous semaglutide treatment against a cycled regimen mimicking real-world patterns of discontinuation and restart.    

‍

The findings showed that intermittent GLP-1 exposure rapidly weakened treatment effectiveness, with reduced response appearing by the second cycle and body weight ending up roughly 20% higher after three cycles compared with continuous treatment. The researchers propose that repeated interruptions cause a buildup of lean mass loss that isn't fully restored during breaks from treatment, so each new cycle starts from a body composition skewed toward more fat and less muscle. This may trigger biological defenses that protect remaining lean tissue at the expense of further fat loss.

‍

Why This Matters Clinically

More than half of patients stop GLP-1 RA therapy within two years, and many later restart it. Related work notes concern that such cycling could worsen sarcopenic obesity risk, particularly in older adults.  

‍

The continued ‘yo-yoing’ off and on GLP-1 therapies over extended periods of time may result in less effective fat loss but more critically continued lean muscle loss, which could pose a major long-term health issue.  

‍

Patients will demand new treatment options, particularly as maintenance therapy where a patient has successfully lost weight but aims to maintain weight loss over time, without cycling on and off GLP-1s. A safe and effective small-molecule approach which induces fat loss but maintains muscle mass and function would be an ideal solution to this long-term health challenge. Additionally, as more patients cycle on and off GLP-1 therapies, increasing treatment resistance will create a need for novel mechanisms capable of overcoming weight-loss plateaus and driving patients toward their target weight.

‍

References

1. Son AJ, et al. Cycling GLP-1 receptor agonist treatment induces therapeutic resistance and increased adiposity. JCI Insight. 2026.

2. Rodriguez PJ, et al. JAMA Netw Open. 2025;8(1):e2457349.

3. West S, et al. BMJ. 2026;392:e085304.